Please wait while the formulary information is being retrieved.
STIVARGA (REGORAFENIB)
- Gastrointestinal stromal tumor
- Liver cell carcinoma
- Metastatic colorectal cancer
40 mg tablet
- 4 tablets (160 mg) by oral route once daily (same time each day)with a low-fat breakfast, on days 1-21 of a 28 day treatment cycle
Gastrointestinal stromal tumor
- 2 tablets (80 mg) by oral route once daily at the same time eachday, swallowing whole with a low-fat breakfast, on days 1 through 21 of a 28 day treatment cycle
- 2 tablets (80 mg) by oral route once daily (same time each day) with a low-fat breakfast, on days 1-21 of a 28 day treatment cycle
- 4 tablets (160 mg) by oral route once daily at the same time each day, swallowing whole with a low-fat breakfast, on days 1 through 21Of a 28 day treatment cycle
- 4 tablets (160 mg) by oral route once daily (same time each day)with a low-fat breakfast, on days 1-21 of a 28 day treatment cycle
Liver cell carcinoma
- 2 tablets (80 mg) by oral route once daily at the same time eachday, swallowing whole with a low-fat breakfast, on days 1 through 21 of a 28 day treatment cycle
- 2 tablets (80 mg) by oral route once daily (same time each day) with a low-fat breakfast, on days 1-21 of a 28 day treatment cycle
- 4 tablets (160 mg) by oral route once daily at the same time each day, swallowing whole with a low-fat breakfast, on days 1 through 21Of a 28 day treatment cycle
- 4 tablets (160 mg) by oral route once daily (same time each day)with a low-fat breakfast, on days 1-21 of a 28 day treatment cycle
Metastatic colorectal cancer
- 2 tablets (80 mg) by oral route once daily at the same time eachday, swallowing whole with a low-fat breakfast, on days 1 through 21 of a 28 day treatment cycle
- 2 tablets (80 mg) by oral route once daily (same time each day) with a low-fat breakfast, on days 1-21 of a 28 day treatment cycle
- 4 tablets (160 mg) by oral route once daily at the same time each day, swallowing whole with a low-fat breakfast, on days 1 through 21Of a 28 day treatment cycle
- 4 tablets (160 mg) by oral route once daily (same time each day)with a low-fat breakfast, on days 1-21 of a 28 day treatment cycle
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- None
Severe
Moderate
- amoxicil-clarithromy-lansopraz
- B cplx-C-St.Johnwrt-K.&S.ginsg
- Belladonna-phenobarbital
- Biaxin
- Biaxin Xl
- Biaxin Xl Pak
- boceprevir
- calcium-mag-B complex-D3-hrb61
- carbamazepine
- Carbatrol
- Cerebyx
- clarithromycin
- Cold & Flu Fighter
- conivaptan in 5 % dextrose
- Crixivan
- Dilantin
- Dilantin Extended
- Dilantin Infatabs
- Dilantin Kapseal
- Dilantin-125
- Donnatal
- Epitol
- Equetro
- Fatigue Relief Complex
- fosphenytoin
- Incivek
- indinavir
- Invirase
- isoniazid-rifamp-pyrazinamide
- itraconazole
- Ketek
- ketoconazole
- Luminal
- Lysodren
- mitotane
- Mycobutin
- Mysoline
- nefazodone
- nelfinavir
- Noxafil
- Omeclamox-pak
- omeprazole-clarith-amoxicillin
- Onmel
- phenobarb-hyoscy-atropine-scop
- phenobarbital
- phenobarbital sodium
- Phenytek
- phenytoin
- phenytoin sodium
- phenytoin sodium extended
- posaconazole
- Prevpac
- primidone
- rifabutin
- Rifadin
- Rifamate
- rifampin
- rifampin-isoniazid
- Rifater
- saquinavir mesylate
- Sporanox
- Sporanox Pulsepak
- St. John's wort
- Tegretol
- Tegretol Xr
- telaprevir
- telithromycin
- Vaprisol
- Vfend
- Vfend Iv
- Victrelis
- Viracept
- vit C-St. John wort-elder-hb30
- voriconazole
- Women's Complex
- Arterial aneurysm
- Arterial dissection
- Drug-induced hepatitis
- Gastrointestinal fistula
- Gastrointestinal perforation
- Lactating mother
- Posterior reversible encephalopathy syndrome
- Surgical wound dehiscence
Contraindicated
- Abnormal hepatic function tests
- Acute myocardial infarction
- Hemorrhage
- Hyperbilirubinemia
- Invasive surgical procedure
- Myocardial ischemia
- Pregnancy
- Severe hepatic disease
- Severe infection
- Severe uncontrolled hypertension
Severe
Moderate
- None
STIVARGA (REGORAFENIB)
- Gastrointestinal stromal tumor
- Liver cell carcinoma
- Metastatic colorectal cancer
- Anemia
- Hemorrhage
- Hypocalcemia
- Hypokalemia
- Hypophosphatemia
- Proteinuria
- Thrombocytopenic disorder
- Acute abdominal pain
- Anorexia
- Diarrhea
- Fatigue
- Fever
- General weakness
- Headache disorder
- Hyperbilirubinemia
- Hypertension
- Impaired wound healing
- Infection
- Nausea
- Pain
- Palmar-plantar erythrodysesthesia
- Skin rash
- Stomatitis
- Voice change
- Weight loss
More Frequent
Severe
Less Severe
- Abnormal hepatic function tests
- Acute myocardial infarction
- Hepatic failure
- Myocardial ischemia
- Alopecia
- Hypothyroidism
- Maculopapular rash
- Muscle rigidity
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Erythema multiforme
- Gastrointestinal fistula
- Gastrointestinal perforation
- Heart failure
- Hepatocellular damage
- Hypersensitivity drug reaction
- Hypertensive crisis
- Nephrotic syndrome
- Posterior reversible encephalopathy syndrome
- Stevens-johnson syndrome
- Toxic epidermal necrolysis
Less Severe
- None
Contraindicated
None
Severe Precaution
Regorafenib
Potential bone growth abnormalities. No safety and efficacy.
- 1 Day – 18 Years
- Potential bone growth abnormalities. No safety and efficacy.
Management or Monitoring Precaution
None
Regorafenib
- Severity Level:
D
- Additional Notes: Insuff human data; based on drug pharmacology and animal data, dev tox can occur
Contraindicated
Regorafenib
Excretion possible due to long half life and low mw, excreted in rats
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Excretion possible due to long half life and low mw, excreted in rats |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Regorafenib has rarely caused very serious (possibly fatal) liver disease, especially in the first 2 months of treatment. People of Asian descent are at greater risk. Your doctor will monitor your liver function before and during treatment with this medication. Tell your doctor right away if you develop new or worsening symptoms of liver disease, such as nausea/vomiting that doesn't stop, severe stomach/abdominal pain, dark urine, yellowing eyes/skin.
| Gastrointestinal stromal tumor | |
| C49.A | Gastrointestinal stromal tumor |
| C49.A0 | Gastrointestinal stromal tumor, unspecified site |
| C49.A1 | Gastrointestinal stromal tumor of esophagus |
| C49.A2 | Gastrointestinal stromal tumor of stomach |
| C49.A3 | Gastrointestinal stromal tumor of small intestine |
| C49.A4 | Gastrointestinal stromal tumor of large intestine |
| C49.A5 | Gastrointestinal stromal tumor of rectum |
| C49.A9 | Gastrointestinal stromal tumor of other sites |
| Liver cell carcinoma | |
| C22.0 | Liver cell carcinoma |
| Metastatic colorectal cancer | |
| C18 | Malignant neoplasm of colon |
| C18.0 | Malignant neoplasm of cecum |
| C18.1 | Malignant neoplasm of appendix |
| C18.2 | Malignant neoplasm of ascending colon |
| C18.3 | Malignant neoplasm of hepatic flexure |
| C18.4 | Malignant neoplasm of transverse colon |
| C18.5 | Malignant neoplasm of splenic flexure |
| C18.6 | Malignant neoplasm of descending colon |
| C18.7 | Malignant neoplasm of sigmoid colon |
| C18.8 | Malignant neoplasm of overlapping sites of colon |
| C18.9 | Malignant neoplasm of colon, unspecified |
| C19 | Malignant neoplasm of rectosigmoid junction |
| C20 | Malignant neoplasm of rectum |
| C21.8 | Malignant neoplasm of overlapping sites of rectum, anus and anal canal |
| 0-9 | A-Z |
|---|---|
| C18 | Malignant neoplasm of colon |
| C18.0 | Malignant neoplasm of cecum |
| C18.1 | Malignant neoplasm of appendix |
| C18.2 | Malignant neoplasm of ascending colon |
| C18.3 | Malignant neoplasm of hepatic flexure |
| C18.4 | Malignant neoplasm of transverse colon |
| C18.5 | Malignant neoplasm of splenic flexure |
| C18.6 | Malignant neoplasm of descending colon |
| C18.7 | Malignant neoplasm of sigmoid colon |
| C18.8 | Malignant neoplasm of overlapping sites of colon |
| C18.9 | Malignant neoplasm of colon, unspecified |
| C19 | Malignant neoplasm of rectosigmoid junction |
| C20 | Malignant neoplasm of rectum |
| C21.8 | Malignant neoplasm of overlapping sites of rectum, anus and anal canal |
| C22.0 | Liver cell carcinoma |
| C49.A | Gastrointestinal stromal tumor |
| C49.A0 | Gastrointestinal stromal tumor, unspecified site |
| C49.A1 | Gastrointestinal stromal tumor of esophagus |
| C49.A2 | Gastrointestinal stromal tumor of stomach |
| C49.A3 | Gastrointestinal stromal tumor of small intestine |
| C49.A4 | Gastrointestinal stromal tumor of large intestine |
| C49.A5 | Gastrointestinal stromal tumor of rectum |
| C49.A9 | Gastrointestinal stromal tumor of other sites |
Formulary Reference Tool